-
CEPI awards up to US$21 million to Themis Bioscience for Phase 3 Chikungunya Vaccine Development
- posted by: Lee Smith
- posted on: June 5, 2019
CEPI awards US$21 million to Themis Bioscience
Read the rest of this post -
Themis Bioscience Enters into a $37.5m Agreement with CEPI to Develop a Lassa Fever and MERS-CoV Vaccine
- posted by: Lee Smith
- posted on: March 7, 2018
Themis Bioscience GmbH, an Austrian based vaccine company, has secured a $37.5m agreement with CEPI to create new vaccines for the infectious diseases Lassa Fever and MERS-CoV.
Read the rest of this post -
Chikungunya Vaccine UK Government Funding Secured By Themis Bioscience
- posted by: Lee Smith
- posted on: September 12, 2017
One year ago in September 2016 the UK's government innovation agency Innovate UK provided £1 million to help accelerate Themis' Zika candidate into the clinic. Now, a year on they are providing another £3 million for clinical trials to help propel the firm's Chikungunya vaccine forward.
Read the rest of this post -
New Article: Public-Private Coalition's: High-Profile Delinkage Policy For Emerging Vaccines
- posted by: Lee Smith
- posted on: July 11, 2017
Recently I've contributed a small part in Tatum Anderson's April 2017 article Public-Private Coalition's: High-Profile Delinkage Policy For Emerging Vaccines.
Read the rest of this post -
CEPI Vaccine Fund
- posted by: Lee Smith
- posted on: January 30, 2017
Last October (2016) I posted an article on whether there should be a global vaccine development fund. Therefore, I was very excited to see an announcement made at the World Economic Forum in Davos, Switzerland on January 18th (2017) that a new global coalition had been formed; the Coalition of Epidemic Preparedness Innovations, or CEPI.
Read the rest of this post -
Should there be a Global Vaccine Development Fund?
- posted by: Lee Smith
- posted on: October 25, 2016
I recently attended the World Vaccine Congress in Barcelona. I joined a round table discussion hosted by Dr. Greg Poland from the Mayo clinic where the question asked was ‘should there be a vaccine development fund?’ The thrust of the discussion was based upon a publication that was made in the New England Journal of Medicine last year about Establishing a Global Vaccine-Development Fund. Vaccine funding is a complex question. Vaccines are probably one of the better value, if not the best, medicinal investments in that they focus on disease prevention rather than treating the consequential symptoms of the disease. Therefore, we might say from a public health economics perspective that vaccines make a lot of sense. But is that true?
Read the rest of this post